JMI Laboratories, North Liberty, IA, USA; University of Iowa College of Medicine, Iowa City, IA, USA.
JMI Laboratories, North Liberty, IA, USA.
J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19.
To evaluate the in vitro activity of ceftolozane-tazobactam and comparator agents tested against isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients in Australia and New Zealand with healthcare-associated infection.
A total of 1459 gram-negative organisms (440 P. aeruginosa and 1019 Enterobacteriaceae) were consecutively collected from 11 medical centers located in Australia and New Zealand. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria.
Ceftolozane-tazobactam (MIC, 0.25/0.5μg/mL; 97.7/95.9% susceptible [CLSI/EUCAST]), meropenem (MIC, ≤0.06/≤0.06μg/mL; 99.8/99.9% susceptible [CLSI/EUCAST]) and amikacin (MIC, 2/4μg/mL; 99.8/99.6% susceptible [CLSI/EUCAST]) were the most active compounds tested against Enterobacteriaceae. Enterobacteriaceae isolates displayed susceptibility rates to other β-lactam agents ranging from 95.3/94.4% for cefepime, 94.1/91.4% for piperacillin-tazobactam, and 93.3/91.5% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates tested, 0.1% were CRE and 6.6% exhibited an ESBL non-CRE phenotype. Whereas ceftolozane-tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC, 0.5/2μg/mL), it lacked useful activity (MIC, >32μg/mL) against the single isolate with a CRE resistant phenotype. Ceftolozane-tazobactam was the most potent (MIC, 0.5/2μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 95.7% at an MIC of ≤4μg/mL.
Ceftolozane-tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin-tazobactam when tested against Enterobacteriaceae.
评估头孢洛扎他唑巴坦和比较剂在澳大利亚和新西兰与医疗保健相关感染的患者的肠杆菌科和铜绿假单胞菌分离株中的体外活性。
从澳大利亚和新西兰的 11 家医疗中心连续收集了 1459 株革兰氏阴性菌（440 株铜绿假单胞菌和 1019 株肠杆菌科）。采用 CLSI M07-A10 文件中描述的肉汤微量稀释法对这些细菌进行药敏试验，并根据 EUCAST 和 CLSI 折点标准进行解释。
头孢洛扎他唑巴坦（MIC，0.25/0.5μg/mL；97.7/95.9%敏感[CLSI/EUCAST]）、美罗培南（MIC，≤0.06/≤0.06μg/mL；99.8/99.9%敏感[CLSI/EUCAST]）和阿米卡星（MIC，2/4μg/mL；99.8/99.6%敏感[CLSI/EUCAST]）是对肠杆菌科最具活性的化合物。肠杆菌科分离株对其他β-内酰胺类药物的敏感性率在头孢吡肟为 95.3/94.4%、哌拉西林他唑巴坦为 94.1/91.4%和头孢他啶为 93.3/91.5%之间，这些数据使用 CLSI/EUCAST 折点。在所测试的肠杆菌科分离株中，有 0.1%为 CRE，有 6.6%表现出非 CRE 型 ESBL 表型。虽然头孢洛扎他唑巴坦对肠杆菌科的 ESBL 非 CRE 表型菌株具有良好的活性（MIC，0.5/2μg/mL），但它对具有 CRE 耐药表型的单个分离株缺乏有用的活性（MIC，>32μg/mL）。头孢洛扎他唑巴坦是对铜绿假单胞菌分离株最有效的（MIC，0.5/2μg/mL）β-内酰胺类药物，在 MIC 为≤4μg/mL 时抑制了 95.7%的菌株。
头孢洛扎他唑巴坦是对铜绿假单胞菌最具活性的β-内酰胺类药物，与目前可用的头孢菌素类和哌拉西林他唑巴坦相比，对肠杆菌科具有更高的体外活性。
